1. Home
  2. EU vs PRTC Comparison

EU vs PRTC Comparison

Compare EU & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo enCore Energy Corp.

EU

enCore Energy Corp.

HOLD

Current Price

$1.99

Market Cap

413.7M

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

N/A

Current Price

$17.70

Market Cap

400.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EU
PRTC
Founded
2009
2015
Country
United States
United States
Employees
N/A
90
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
413.7M
400.2M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
EU
PRTC
Price
$1.99
$17.70
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
2.2M
3.6K
Earning Date
05-11-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
N/A
EPS
N/A
N/A
Revenue
$43,155,000.00
N/A
Revenue This Year
$212.11
N/A
Revenue Next Year
$29.88
N/A
P/E Ratio
N/A
$8.09
Revenue Growth
N/A
N/A
52 Week Low
$1.50
$14.50
52 Week High
$4.19
$19.92

Technical Indicators

Market Signals
Indicator
EU
PRTC
Relative Strength Index (RSI) 48.94 58.79
Support Level $1.71 $16.60
Resistance Level $2.17 $18.20
Average True Range (ATR) 0.14 0.50
MACD 0.04 0.18
Stochastic Oscillator 58.51 76.16

Price Performance

Historical Comparison
EU
PRTC

About EU enCore Energy Corp.

enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: